L3VLUP
ProSign in

VRTX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VRTXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VRTX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterVRTXLLY
Q3 202031 holders, $21.9bn33 holders, $14.1bn
Q4 202030 holders, $18.4bn29 holders, $17.3bn
Q1 202131 holders, $15.4bn24 holders, $23.0bn
Q2 202130 holders, $12.7bn24 holders, $27.8bn
Q3 202135 holders, $10.1bn31 holders, $29.9bn
Q4 202128 holders, $12.4bn31 holders, $34.7bn
Q1 202223 holders, $16.1bn24 holders, $35.3bn
Q2 202225 holders, $18.1bn33 holders, $42.7bn
Q3 202222 holders, $18.4bn31 holders, $43.4bn
Q4 202228 holders, $18.4bn31 holders, $46.6bn
Q1 202326 holders, $21.4bn33 holders, $44.3bn
Q2 202327 holders, $24.7bn37 holders, $59.6bn
Q3 202333 holders, $24.3bn44 holders, $67.6bn
Q4 202332 holders, $28.6bn45 holders, $73.6bn
Q1 202431 holders, $29.8bn41 holders, $95.3bn
Q2 202429 holders, $33.4bn43 holders, $110bn
Q3 202427 holders, $33.5bn45 holders, $107bn
Q4 202426 holders, $28.5bn46 holders, $93.9bn
Q1 202521 holders, $35.4bn42 holders, $98.4bn
Q2 202521 holders, $32.3bn43 holders, $93.2bn
Q3 202522 holders, $25.9bn39 holders, $86.7bn
Q4 202526 holders, $31.8bn41 holders, $123bn
Q1 202625 holders, $31.8bn39 holders, $106bn
Q2 202626 holders, $34.6bn44 holders, $132bn
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VRTX (4)

ARK Investment Management LLC, Baillie Gifford & Co, MFS Investment Management, Two Sigma Advisers LP

Only LLY (19)

AQR Capital Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, D. E. Shaw & Co., Dodge & Cox, Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Jane Street Group LLC, Moore Capital Management LP, Point72 Asset Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Soros Fund Management LLC, Steadfast Capital Management LP, Tudor Investment Corp, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →